ArticleMolecular genetics and genomics : MGG2026
Targeting WWP1 ameliorates osteoarthritis by suppressing KLF15 ubiquitination to restore mtDNA and mitochondrial function.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteoarthritis (OA), the most prevalent chronic joint disease and a leading cause of disability, is mechanistically linked to mitochondrial dysfunction in its pathogenesis. This study aimed to elucidate the regulatory role and therapeutic potential of the WWP1/KLF15/TFAM signaling axis in OA-associated mitochondrial impairment. We demonstrate that in OA chondrocytes, the E3 ubiquitin protein ligase 1 (WWP1) promotes ubiquitination and degradation of the transcription factor KLF15, reducing its protein stability. The krüppel-like factor 15 (KLF15) directly binds to the promoter of the mitochondrial transcription factor A (TFAM) and activates its transcription. Under OA conditions, TFAM expression is downregulated; restoring TFAM expression significantly enhances mitochondrial DNA (mtDNA) transcription and replication, upregulates mitochondrial-encoded genes, repairs mitochondrial membrane potential (ΔΨm), and reduces superoxide levels, thereby improving mitochondrial function and reversing metabolic dysregulation in chondrocytes. In conclusion, our findings reveal that WWP1 impairs mtDNA biogenesis by mediating KLF15 ubiquitination and degradation, leading to suppressed TFAM transcription. This results in reduced expression of mitochondrial-encoded genes and mitochondrial dysfunction, which collectively exacerbate OA pathogenesis. These insights identify the WWP1/KLF15/TFAM axis as a promising therapeutic target for OA.
Indexed as
Identifiers
42029952What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.